title: Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
abstract: The treatment with α1-blockers in patients complaining of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) is associated with potential adverse events (AEs), thus including ejaculatory dysfunction (EjD). We sought to assess the effects of a 3-month course of silodosin 8 mg daily dosing on sexual functioning, mainly including ejaculation and orgasm, in a cohort of 100 consecutive sexually active men in the real-life setting. Patients completed the International Index of Erectile Function-Orgasmic Function (IIEF-OF) domain and the International Prostate Symptom Score (IPSS) both at baseline and at survey. Likewise, patients completed a 16-item self-administered questionnaire with closed questions also including specific questions regarding treatment-related adverse events on sexual functioning. Rates and predictors of OF impairment and drug discontinuation were investigated. At survey, silodosin resulted highly effective in improving IPSS-total and subscales (all p < 0.01). Anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 (11%), 6 (6%), 7 (7%) and 11 (11%) patients respectively. Overall, a reduction in IIEF-OF domain score was observed in 64 (64%) patients. Patients with decreased IIEF-Q9 and/or IIEF-Q10 scores were significantly younger than those without any decrease (p = 0.02). Of all, only 7% of the patients discontinued silodosin because of anejaculation. Silodosin confirms to be highly effective in patients with LUTS/BPH; of them, almost 70% report either anejaculation or hypospermia, with a concomitant OF impairment in 17% of the patients. Younger patients showed higher rates of a concomitant impairment of ejaculation and OF. Overall, anejaculation caused drug discontinuation in 7% of the patients.
authors.affiliation: Università Vita-Salute San Raffaele, Milan, Italy.|Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Capogrosso
authors.affiliation: Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Serino
authors.affiliation: Università Vita-Salute San Raffaele, Milan, Italy.|Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Ventimiglia
authors.affiliation: Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Boeri
authors.affiliation: Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Dehò
authors.affiliation: Research Doctorate Program in Urology, Magna Graecia University, Catanzaro, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Damiano
authors.affiliation: Università Vita-Salute San Raffaele, Milan, Italy.|Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.|Research Doctorate Program in Urology, Magna Graecia University, Catanzaro, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Briganti
authors.affiliation: Università Vita-Salute San Raffaele, Milan, Italy.|Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Montorsi
authors.affiliation: Università Vita-Salute San Raffaele, Milan, Italy.|Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Salonia
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004542:Ejaculation / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009845:Oligospermia / Q000139:chemically induced / Q000503:physiopathology; D015995:Prevalence; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012307:Risk Factors; D012725:Sexual Behavior / Q000187:drug effects*; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology; D013091:Spermatogenesis / Q000187:drug effects; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D064804:Urological Agents / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D007211:Indoles; D064804:Urological Agents; C095285:silodosin
keywords: benign prostatic hyperplasia; ejaculatory dysfunction; sexual dysfunction; silodosin